Hypotensors
AssigneeYuichi Ishida
InventorsYuichi Ishida, Fumiaki Suzuki, Kazu Murakami
Life of this patent
Estimating the term…
Abstract
There are provided a method for selection of a substance which is capable of controlling activation of prorenin where an adjusting ability of the activation of prorenin by protein-protein interaction in a profragment region of prorenin as indicator is used; a prorenin activation controlling substance having a function of controlling the activation of prorenin based on protein-protein interaction by a profragment region of prorenin; and hypotensor, organ hypertrophy suppressor and arterial thickening suppressor containing the said prorenin activation controlling substance as an effective ingredient.
Claims35
A method for selection of a substance capable of controlling activation of prorenin in which the method is carried out using, as an indicator, an adjusting ability of the activation of prorenin which occurs by protein-protein interaction in the profragment region of prorenin without alteration in a primary structure.
A method for selection of a substance capable of controlling activation of prorenin in which the method is carried out using, as an indicator, an adjusting ability of the activation of prorenin by an antibody against the profragment region of prorenin.
A prorenin activation controlling substance having a function of controlling activation of prorenin which occurs by protein-protein interaction in the profragment region of prorenin without alteration in a primary structure.
A prorenin activation controlling substance having a function of inhibiting activation of prorenin which occurs by protein-protein interaction in the profragment region of prorenin without alteration in a primary structure.
A prorenin activation controlling substance having a function of inhibiting activation of prorenin which occurs by protein-protein interaction in the profragment region of prorenin without alteration in a primary structure and retaining no renin-inhibiting activity.
A prorenin activation controlling substance comprising a peptide having a partial sequence selected from amino acid sequence of profragment region of prorenin or an equivalent peptide thereto and having a function of inhibiting activation of prorenin which occurs by protein-protein interaction in the profragment region of prorenin without alteration in a primary structure.
A prorenin activation controlling substance comprising a peptide having a continued 3 to 10 partial sequence selected from amino acid sequence of profragment region of prorenin and having a function of inhibiting activation of prorenin which occurs by protein-protein interaction in the profragment region of prorenin without alteration in a primary structure.
A prorenin activation controlling substance comprising a peptide having a continued 3 to 8 partial sequence selected from amino acid sequence of profragment region of prorenin and having a function of inhibiting activation of prorenin which occurs by protein-protein interaction in the profragment region of prorenin without alteration in a primary structure.
A prorenin activation controlling substance comprising a peptide having a continued 3 to 6 partial sequence selected from amino acid sequence of profragment region of prorenin and having a function of inhibiting activation of prorenin which occurs by protein-protein interaction in the profragment region of prorenin without alteration in a primary structure.
A prorenin activation controlling substance comprising a peptide selected from the peptide mentioned in SEQ ID NO:
- 7 to NO:
- 14 of the Sequence Listing and having a function of inhibiting activation of prorenin which occurs by protein-protein interaction in the profragment region of prorenin without alteration in a primary structure.
A prorenin activation controlling substance comprising a peptide selected from the peptide mentioned in SEQ ID NO:
- 3, NO:
- 4 and from NO:
- 15 to NO:
- 20 of the Sequence Listing and having a function of inhibiting activation of prorenin which occurs by protein-protein interaction in the profragment region of prorenin without alteration in a primary structure.
A prorenin activation controlling substance having a function of inhibiting activation of prorenin which occurs by protein-protein interaction in the profragment region of prorenin without alteration in a primary structure, wherein the substance is a low-molecular compound designed from the information of amino acid sequence of profragment region of prorenin.
A prorenin activation controlling substance which is characterized in that activation of prorenin is inhibited in vivo by removal of prorenin based on an antigen-antibody reaction to the profragment region of prorenin.
A prorenin activation controlling substance comprising an antibody against the profragment region of prorenin which is capable of inhibiting the prorenin activation in vivo by removal of prorenin based on an antigen-antibody reaction to the profragment region of prorenin.
Dependencies are inferred from the claim text.